Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phesgo vs IV Pertuzumab/Trastuzumab in HER2+ Early Breast Cancer
NCT04024462Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04024462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024462.